$3.76
Today
as of Aug 5, 16:53 ET
Last 30 days
Recent Press Releases & News
Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026
Biomarker Collaboration and Licensing Deals Report 2016-2026 - Featuring Quanterix, Caris Life Sciences, Alnylam Pharmaceuticals, Guardant Health, Eurofins Scientific and More
Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Overview
52-week range
$2.40
$8.77
21% of range
Avg surprise (last 3)
-5.8%
Avg reaction (last 2)
+4.1%
50% positive
Latest IV / EM
454%
EM ±75.8% · $5 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 6, 2026 | Mar/2026 | $-0.39 | $-0.31 | -25.8% | +26.4% | -0.3% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.73 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.47 | $-0.41 | -14.6% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.53 | $-0.69 | +23.2% | — | +8.5% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.22 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.19 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.29 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.18 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.15 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | — | -$0.47 |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | $21M | — | $23M | $13M | $15M | — | $16M | $12M |
| Gross profit | $16M | — | $17M | $11M | $15M | — | $20M | $22M |
| Operating income | $-41M | — | $-37M | $-37M | $-26M | — | $-12M | $-11M |
| Net income | $-18M | — | $-34M | $-30M | $-21M | — | $-8M | $-7M |
| EPS (diluted) | $-0.37 | — | $-0.73 | $-0.77 | $-0.53 | — | $-0.22 | $-0.19 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $36M | $30M | $38M | $133M | $77M | $57M | $29M | $47M |
| Inventory | $51M | $55M | $55M | $30M | $31M | $33M | $33M | $33M |
| Total current assets | $186M | $212M | $233M | $322M | $335M | $364M | $367M | $370M |
| Total assets | $367M | $419M | $444M | $376M | $397M | $407M | $411M | $416M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $85M | $123M | $130M | $83M | $80M | $76M | $72M | $75M |
| Total equity | $282M | $296M | $315M | $292M | $316M | $330M | $339M | $341M |